The current financial score of 111 Inc is 7.06. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 348.65M, representing a year-over-year decrease of 28.99%, while its net profit experienced a year-over-year decrease of 122.72%.
The current valuation score of 111 Inc is 9.58. Its current P/E ratio is -32.99, which is -99.65% below the recent high of -0.11 and -90.83% above the recent low of -62.96.
No earnings forecast score is currently available for 111 Inc. The Pharmaceuticals industry's average is 7.86.
The current price momentum score of 111 Inc is 6.96. Currently, the stock price is trading between the resistance level at 4.22 and the support level at 2.83, making it suitable for range-bound swing trading.
The current institutional shareholding score of 111 Inc is 3.00. The latest institutional shareholding proportion is 6.89%, representing a quarter-over-quarter increase of 446.56%. The largest institutional shareholder is James Simons, holding a total of 12.91K shares, representing 0.00% of shares outstanding, with 50.96% decrease in holdings.
The current risk assessment score of 111 Inc is 2.83. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.